Russians love Putin's dustup with the West. But they've stopped spending money
Why rival discounters are vying for control of Family Dollar Stores
Twitter's head of product, Daniel Graf, must make the service more user-friendly without offending hard-core fans
Yale's Robert Shiller is sending up warning flares. It may be best to ignore him
To minimize flood chaos, turn the hospital upside down
Bayer is marketing Berocca as performance drink, but Australians know what it's really for
After years of effort, top B-schools still enroll only about 40 percent female MBAs
Advice for a small bed-and-breakfast trying to get on the map for international tourists
King of Prussia, Pa.
Founders: Dr. Robert Lefkowitz and Dr. Howard Rockman
VC Investment over the last four quarters: $26.1 million
Trevena, founded in January 2008, is a drug discovery company developing pharmaceuticals that target what are known as G-protein coupled receptors. Such drugs make up more than 40% of marketed drugs today, according to Trevena. The company's drug discovery platform is based on research from Duke University Medical Center, including that of founder and National Medal of Science winner Robert Lefkowitz.
Key to startup success: "We've been able to generate the strong investor support for this idea [because] the technology and the opportunity here is very, very unique, and the possibility of unlocking new areas of biology is so significantly different from what's currently out there."